CTI BioPharma Corp.
CTIC · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $54 | $0 | $0 | $3 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $4 | $0 | $4 | $0 |
| Gross Profit | $50 | -$0 | -$4 | $3 |
| % Margin | 93.5% | – | – | 100% |
| R&D Expenses | $37 | $39 | $26 | $24 |
| G&A Expenses | $0 | $0 | $18 | $0 |
| SG&A Expenses | $85 | $56 | $18 | $19 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $9 | -$0 | $4 | $0 |
| Operating Expenses | $130 | $95 | $48 | $43 |
| Operating Income | -$80 | -$95 | -$48 | -$41 |
| % Margin | -147.9% | – | – | -1,217.1% |
| Other Income/Exp. Net | -$13 | -$3 | -$5 | $1 |
| Pre-Tax Income | -$93 | -$98 | -$52 | -$40 |
| Tax Expense | -$2 | $2 | $1 | $2 |
| Net Income | -$91 | -$100 | -$53 | -$42 |
| % Margin | -168.8% | – | – | -1,265.1% |
| EPS | -0.79 | -1.11 | -0.74 | -0.73 |
| % Growth | 28.8% | -50% | -1.4% | – |
| EPS Diluted | -0.79 | -1.11 | -0.74 | -0.73 |
| Weighted Avg Shares Out | 115 | 90 | 71 | 58 |
| Weighted Avg Shares Out Dil | 115 | 90 | 71 | 58 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $0 | $0 | $1 |
| Interest Expense | $13 | $2 | $1 | $2 |
| Depreciation & Amortization | -$0 | -$0 | $0 | $3 |
| EBITDA | -$80 | -$95 | -$51 | -$37 |
| % Margin | -148% | – | – | -1,118.8% |